Egleston Law Firm Announces Investigation of the Acquisition of Martek Biosciences Corporation
December 30 2010 - 6:30PM
Business Wire
Egleston Law Firm announces an investigation into possible
breaches of fiduciary duty in connection with the proposed
acquisition of Martek Biosciences Corporation (NASDAQ: MATK)
(“Martek” or the “Company”) by Royal DSM N.V. (“DSM”) in an all
cash tender offer valued at approximately $1.087 billion.
Under the terms of the definitive agreement, Martek shareholders
will receive $31.50 in cash for each share they own of the
Company’s common stock. The acquisition is structured as an
all-cash tender offer to be followed by a merger in which each
remaining share of Martek common stock would be converted into the
same cash per share price paid in the tender offer. The tender
offer is expected to commence between January 10 and January 25,
2011, and to close in February 2011. The acquisition is expected to
close in the first or second quarter of 2011. The investigation is
focused on whether the proposed deal provides adequate value to
Martek’s shareholders.
If you are a shareholder of Martek and would like more
information about our investigation, please contact Gregory M.
Egleston, Esq. by telephone at (646) 227-1700 or by e-mail at
greg.egleston@gmail.com or visit www.gme-law.com.
ATTORNEY ADVERTISING. Prior results do not guarantee or predict
a similar outcome with respect to any future matter.
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Aug 2023 to Aug 2024